Amryt Due For Oral Explanation At EMA For Epidermolysis Bullosa Gel Filsuvez
Capmatinib Developer May Also Make Its Case Before The CHMP
Amryt Pharmaceuticals is set to appear before the European Medicines Agency to explain why its treatment for patients with epidermolysis bullosa merits EU-wide approval. The drug was recently rejected in the US.
